Lifeward Ltd. · NASDAQ:LFWD
Lifeward — ReWalk Robotics — Investor Presentation (November 2018)
22 slides from Lifeward's investor presentation, Nov 13, 2018
Slide 1: Human and Robotic Intersection: Take the Next Step
Human and Robotic Intersection Take the Next Step 1 November 2018 ReWalk Confidential. © 2018 ReWalk Robotics, Inc.
Slide 2: Disclaimer
Disclaimer This presentation contains statistical data that were obtained from industry publications and reports generated by third parties. Although ReWalk believes that the publications and reports are reliable, it has not independently verified this statistical d ata . The trademarks included her
Slide 3: Forward Looking Statements
Forward Looking Statements In addition to historical information, this presentation contains forward - looking statements within the meaning of Section 27 A of the Securities Act, Section 21 E of the Exchange Act, and the safe harbor provisions of the U . S . Private Securities Litigation Reform Act
Slide 4: Our Mission
Fundamentally change the Quality of Life for individuals with lower limb disability through the creation and development of market leading robotic technologies Our Mission www.rewalk.com 4
Slide 5: ReWalk Overview
ReWalk rigid exoskeleton • Assists individuals with spinal cord injury to stand and walk • FDA & CE mark clearance • Sixth generation device • Commercialized with 450+ systems worldwide • First mover advantage ReStore soft exo - suit • In development for stroke patients and other lower limb disabili
Slide 6: Multiple Markets for Growth
Multiple Markets for Growth Significant Mobility Impairment TODAY • 282,000 people in the U.S. living with SCI 1 • 17,000 new cases annually FUTURE POTENTIAL • 1,000+ US primary stroke centers 2 , ~100,000 general rehab clinics 3 • EU market similar to US • 6,000+ rehab hospitals in China 4 • 200,00
Slide 7: Breakthrough Technology Addresses the SCI Need
www.rewalk.com Breakthrough Technology Addresses the SCI Need ___________________________ 1. Source: https:// www.nscisc.uab.edu/Public/Facts%202016.pdf 2. Source : https://www.nscisc.uab.edu/public/2016%20Annual%20Report%20 - % 20Complete%20Public%20Version.pdf Wheelchair confinement can cause seve
Slide 8: ReWalk's Breakthrough Technology
ReWalk’s Breakthrough Technology Patented tilt - sensor technology mimics natural gait 8 https://www.youtube.com/watch?v=d5zl7fglMgo
Slide 9: Refined Reimbursement Strategy
Refined Reimbursement Strategy Coverage Decisions Insurers and Direct = Complete 30+ policy submissions for coverage with regional and national insurers in 2018 = US - Utilize VA SOP updated in June 2018 with new Veterans Choice Program to optimize coverage = Secured near universal coverage in Germa
Slide 10: VA National Coverage Policy and Research Study
• First national coverage policy updated in June 2018 • For evaluation, training and issuance of ReWalk exoskeletons • Exclusive to ReWalk exoskeletons • Large multi - center community based exoskeleton study • Evaluating quality of life and health benefits of walking Scope • ~44,000 Paralyzed Indiv
Slide 11: German Medical Aid Code for ReWalk Personal 6.0
Medical Aid Code : 23.29.01.2001 ReWalk Personal 6.0: first and only exoskeleton officially recognized as a medical aid throughout Germany. German SCI market has 80,000 1 paralyzed individuals Official publication in Federal Gazette on June 11, 2018 The listing enables any medically qualified indivi
Slide 12: ReStore - Shaping the Future
ReStore - Shaping the Future • Initially targeting rehabilitation related to stroke • Technology licensed from Harvard • Provides powered plantarflexion • Clinical trial enrollment underway • CE mark submission at the beginning of Q4 2018; FDA submission is planned by Q1 2019; commercialization in E
Slide 13: ReStore in Action
ReStore in Action • Light, soft components and powered dorsi / plantar flexion facilitate natural gait pattern • Provides therapist real - time analytics and enhanced session control for optimized results • Multiple modes of function and rapid donning/ doffing and adjustment for efficient therapy se
Slide 14: Real Time Analytics and Control
Real Time Analytics and Control 14 www.rewalk.com
Slide 15: Near-term ReStore Market: Stroke
Near - term ReStore Market: Stroke US: 7 million stroke survivors 1 EU: 9.6 million stroke survivors 2 China: 11 million stroke survivors ⁸ US: 2.5 million 5,6 potentially eligible for ReStore system EU: 3.4 million 7 potentially eligible for ReStore system China: 3.9 million 7 US: ~ 795K 3 EU / Wes
Slide 16: ReStore Value Proposition for Clinics
16 www.rewalk.com • Reduce staffing or equipment needs, reduce strain on staff Efficiency and Cost Effectiveness • Higher level and consistency of care at less specialized facilities and across PT capability levels Improved Standard of Care • Current technology in competitive marketplace, attract cl
Slide 17: ReStore Multi-Center Clinical Trial
ReStore Multi - Center Clinical Trial OBJECTIVES: • Assess safety of ReStore device during gait training in post - stroke individuals • Evaluate use of ReStore device during common assessments (e.g. 6 minute walking test (6MWT), 10 meter walking test (10MWT)) DESIGN: • 40 patients; 7 sessions • 5 of
Slide 18: Planned Steps For Growth
Planned Steps For Growth — Growing Current Business and Expanding to New Markets ReWalk plans to grow the SCI, Rigid exoskeleton business through expanded coverage policies and develop new soft exosuit technologies through the Wyss partnership to address other lower limb disabilities and create a br
Slide 19: Strategic Approach – China
Strategic Approach – China • Large market opportunity in China • 11 million stroke survivors 1 • 2.4 million people suffer a stroke each year 2 • Number of stroke rehabilitation centers in China expected to exceed those in the US and EU combined by 2021 • March 2018: ReWalk signed a $20 million stra
Slide 20: Financial Snapshot
Financial Snapshot 128 149 218 226 Q3 '15 Q3 '16 Q3 '17 Q3 '18 Pending Insurance Claims $4.0 $3.7 $5.9 $7.8 $5.0 Revenue ($M) www.rewalk.com 20 74 73 119 107 66 Units Placed
Slide 21: Company Highlights
Company Highlights • Market leading global exoskeleton developer with two breakthrough device platforms • Rigid ReWalk exoskeleton for spinal cord injury market • FDA and CE mark clearance for both Personal and Rehabilitation use; sixth generation device • 500 systems placed, with majority for home
Slide 22: Take the Next Step
Take the Next Step 22 www.rewalk.com
ReWalk Robotics — Investor Presentation (November 2018) on 6ix